# Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma

> **NCT05964101** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Guangzhou Medical University** · enrollment: 25 (estimated)

## Conditions studied

- Neoplasms
- Carcinoma, Squamous
- Antineoplastic Agents

## Interventions

- **DRUG:** Nivolumab Injection [Opdivo]

## Key facts

- **NCT ID:** NCT05964101
- **Lead sponsor:** The First Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-01
- **Primary completion:** 2025-08-01
- **Final completion:** 2026-05-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2024-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05964101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05964101, "Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05964101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*